Liquidia Technologies Inc (LQDA) saw its stock soar 5.01% in Monday's trading session, as investors appear to be recognizing the company's strong growth potential and recent regulatory achievements. The biopharmaceutical company, which focuses on developing and commercializing products for unmet patient needs, has been gaining attention for its promising outlook.

A key driver of the stock's upward movement could be the recent FDA approval of YUTREPIA, Liquidia's innovative inhalation powder for pulmonary arterial hypertension. This approval marks a significant milestone for the company, despite ongoing patent litigation with United Therapeutics. Additionally, Liquidia is forecasted to experience substantial revenue growth, with analysts projecting an impressive 43.8% annual expansion rate, far surpassing the US market average.

Investors may also be encouraged by Liquidia's future profitability prospects, with the company expected to achieve profitability within the next three years. This positive outlook, combined with the fact that the stock is currently trading below its estimated fair value, could be fueling the increased buying interest. Furthermore, the 11% insider ownership in Liquidia suggests a strong belief in the company's potential from those closest to its operations, potentially adding to investor confidence and contributing to the stock's upward momentum.